Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11763196 | 0.97 | SNCA (0.41) | SNCAGAAARPOLBKDM4E | |
| SCHEMBL1472475 | 0.95 | SNCA (0.38) | SNCAGAAARPOLBKDM4E | |
| SCHEMBL1470385 | 0.94 | SNCA (0.37) | SNCAGAAARPOLBKDM4E | |
| SCHEMBL1472458 | 0.94 | SNCA (0.39) | SNCAGAAARPOLBKDM4E | |
| SCHEMBL12592413 | 0.94 | SNCA (0.43) | SNCAGAAARPOLBKDM4E | |
| SCHEMBL1470932 | 0.89 | SNCA (0.40) | SNCAGAAARKDM4EALDH1A1 | |
| Iodide SCHEMBL16496799 | 0.89 | SNCA (0.36) | SNCAGAAARPOLBKDM4E | |
| Iodide SCHEMBL3714596 | 0.89 | NOX1 (0.50) | SNCAGAAARPOLBKDM4E | |
| Iodide SCHEMBL3714591 | 0.89 | NOX1 (0.50) | SNCAGAAARPOLBKDM4E | |
| Iodide SCHEMBL3714593 | 0.89 | NOX1 (0.50) | SNCAGAAARPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687286-A1 | DEVELOPMENTS IN BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES (2) | Photopharmica Limited (GB) | 2006-08-09 | — | — | EP | claimed |
| WO-2005054217-A1 | DEVELOPMENTS IN BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES (2) | PHOTOPHARMICA LIMITED (GB) | 2005-06-16 | — | — | WO | claimed |
| US-20040147508-A1 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED | 2004-07-29 | — | — | US | claimed |
| US-20120302557-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | PHOTOPHARMICA LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8188074-B2 | Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy | PHOTOPHARMICA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-7915254-B2 | Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents | PHOTOPHARMICA LIMITED (GB) | 2011-03-29 | — | — | US | disclosed |
| US-7855197-B2 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED (GB) | 2010-12-21 | — | — | US | disclosed |
| US-7732439-B2 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20080312219-A1 | Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy | PHOTOPHARMICA LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080275033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | PHOTOPHARMICA LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080268033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | PHOTOPHARMICA LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080261960-A1 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-7371744-B2 | Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents | PHOTOPHARMICA LIMITED (GB) | 2008-05-13 | — | — | US | disclosed |
| EP-1687286-A1 | DEVELOPMENTS IN BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES (2) | Photopharmica Limited (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054217-A1 | DEVELOPMENTS IN BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES (2) | PHOTOPHARMICA LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| US-20040147508-A1 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261960-A1 | Biologically active methylene blue derivatives | XPA, XPOT, XPO7 | SNCA 3060/4885GAA 3733/4885AR 1400/4885 |
| US-20120302557-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | NR2E3, NR1I3, NR0B2 | SNCA 4295/4885GAA 4534/4885AR 1010/4885 |
| US-20040147508-A1 | Biologically active methylene blue derivatives | HCCS, CYBA, HMBS | SNCA 2236/4885GAA 3678/4885AR 1535/4885 |
| US-20080268033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | XPA, XPOT, XPO4 | SNCA 1789/4885GAA 3513/4885AR 776/4885 |
| US-20080312219-A1 | Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy | XPA, XPOT, XPO4 | SNCA 3248/4885GAA 2499/4885AR 1687/4885 |
| US-20080275033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | XPA, XPO7, XPO4 | SNCA 1355/4885GAA 3578/4885AR 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.